ADMA Biologics (NASDAQ: ADMA) Posts $114.5M Q1 Revenue as ASCENIV Label Expands

ADMA Biologics, Inc. (NASDAQ: ADMA) reported first-quarter 2026 net income of $45.3 million ($0.19 per share) on total revenue of $114.5 million, flat year-over-year, as a sharp divergence between its two lead products defined the period. The results arrived alongside an FDA approval expanding the ASCENIV label to include pediatric immunocompromised patients aged two and older — a regulatory milestone confirmed via an 8-K filing on May 4, 2026.

Q1 2026 At a Glance

• Total revenue: $114.5 million, unchanged year-over-year
• ASCENIV revenue: grew +28% year-over-year
• BIVIGAM revenue: declined -54% year-over-year
• Net income: $45.3 million, or $0.19 per share
• Adjusted net income: $40.7 million, down 22% year-over-year
• Net margin: 28.8% | Gross margin: 57.4%
• Market cap: $2.3 billion | Trailing P/E: 16.8x | Forward P/E: 8.0x

What Drove the Results

The quarter's flat top line masks a meaningful product mix shift. ASCENIV's 28% revenue increase reflects growing adoption of the company's higher-margin plasma-derived immunoglobulin therapy, while BIVIGAM's 54% revenue decline weighed heavily on the aggregate. ADMA Biologics positions itself as a U.S.-based, end-to-end commercial biopharmaceutical company, meaning it controls manufacturing through to commercialization — a structure that supports the 57.4% gross margin despite the product headwinds.

The FDA's approval of the supplemental Biologics License Application for ASCENIV — covering the pediatric post-marketing commitment under Section 351(a) of the Public Health Service Act — also updates the product's prescribing information. This label broadening into patients two years and older addresses an additional patient population and could support future revenue diversification within the ASCENIV franchise.

Wall Street View

Analyst sentiment on (NASDAQ: ADMA) remained broadly constructive into the results. As of May 1, 2026, the consensus stood at 2 Strong Buy, 6 Buy, 2 Hold, and 0 Sell ratings. Compared to the prior month's tally of 2 Strong Buy, 5 Buy, and 2 Hold, one additional analyst moved to a Buy rating — a modest but directionally positive shift in coverage.

Investor Takeaway

ADMA Biologics' first quarter illustrates a business in transition, with ASCENIV gaining commercial momentum while BIVIGAM faces a significant revenue contraction. The forward P/E of 8.0x against a trailing P/E of 16.8x suggests the market is pricing in meaningful earnings improvement ahead, consistent with the company's 15.9% year-over-year revenue growth trend. The pediatric label expansion for ASCENIV, confirmed by the May 8-K filing, adds a regulatory tailwind that analysts appear to be factoring into their predominantly Buy-oriented consensus.